Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (161-170 of 317) with videos related to

Pageof 32
Sort By:
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2025
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanomaMees D Egeler, Sebastian Klobuch, Willemijn S Tak, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Cell|May 4, 2020
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaHanjie Li, Anne M van der Leun, Ido Yofe, et al.
Journal for Immunotherapy of Cancer|April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanomaJudith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
Cell|January 1, 2019
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaHanjie Li, Anne M van der Leun, Ido Yofe, et al.
Nature|August 17, 2017
Identification of CMTM6 and CMTM4 as PD-L1 protein regulatorsRiccardo Mezzadra, Chong Sun, Lucas T Jae, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Pageof 32

Showing results (161-170 of 317) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2025
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanomaMees D Egeler, Sebastian Klobuch, Willemijn S Tak, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Cell|May 4, 2020
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaHanjie Li, Anne M van der Leun, Ido Yofe, et al.
Journal for Immunotherapy of Cancer|April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanomaJudith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
Cell|January 1, 2019
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaHanjie Li, Anne M van der Leun, Ido Yofe, et al.
Nature|August 17, 2017
Identification of CMTM6 and CMTM4 as PD-L1 protein regulatorsRiccardo Mezzadra, Chong Sun, Lucas T Jae, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Pageof 32